Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA 2 DS 2 -VASc Risk Factor Be Anticoagulated? | Zendy

Laurent Fauchier | Zendy; Nicolas Clémenty | Zendy; Arnaud Bisson | Zendy; Fabrice Ivanès | Zendy; Denis Angoulvant | Zendy; Dominique Babuty | Zendy; Gregory Y.H. Lip | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA ₂ DS ₂ -VASc Risk Factor Be Anticoagulated?

Author(s) -

Laurent Fauchier,

Nicolas Clémenty,

Arnaud Bisson,

Fabrice Ivanès,

Denis Angoulvant,

Dominique Babuty,

Gregory Y.H. Lip

Publication year - 2016

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.116.013253

Subject(s) - medicine , atrial fibrillation , risk factor , cardiology , stroke (engine) , ischemic stroke , ischemia , mechanical engineering , engineering

There is some uncertainty about treating patients with atrial fibrillation (AF) with 1 nongender-related (NGR) stroke risk factor (CHA2DS2-VASc [ie, congestive heart failure, hypertension, age (≥75 years; 2 points), diabetes, stroke/transient ischemic attack (2 points), vascular disease, age (65-74 years), sex (female)] score of 1 in males and 2 in females) with oral anticoagulation (OAC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research